Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2018, Article ID 9780489, 8 pages
https://doi.org/10.1155/2018/9780489
Review Article

Heparin-Based Nanoparticles: An Overview of Their Applications

1Laboratorio de Investigación Interdisciplinaria, Área de Nanoestructuras y Biomateriales, Escuela Nacional de Estudios Superiores Unidad León, Universidad Nacional Autónoma de México (UNAM), Boulevard UNAM No. 2011, Predio El Saucillo y El Potrero, 37684 León, GTO, Mexico
2Centro de Investigaciones en Óptica, AP 1-948, 37150 León, GTO, Mexico

Correspondence should be addressed to Maria del Pilar Rodriguez-Torres; moc.liamg@serrot.zdr.ralip

Received 26 June 2017; Accepted 19 November 2017; Published 14 January 2018

Academic Editor: Faheem Ahmed

Copyright © 2018 Maria del Pilar Rodriguez-Torres et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Heera and S. Shanmugan, “Nanoparticle characterization and application: an overview,” International Journal of Current Microbiology and Applied Sciences, vol. 4, no. 8, pp. 379–386, 2015. View at Google Scholar
  2. S. Hasan, “Review on nanoparticles: their synthesis and types,” Research Journal of Recent Sciences, vol. 4, pp. 1–3, 2014, Uttar Pradesh (Lucknow Campus). View at Google Scholar
  3. L. M. Liz-Marzán and P. V. Kamat, Nanoscale Materials. In Nanoscale Materials, p. 1–3, Springer US, 1st edition, 2003.
  4. J. M. Patra, D. Gitishree, and K. H. Baek, “Towards a greener environment: Synthesis and applications of green nanoparticles,” Pakistan Journal of Agricultural Sciences, vol. 53, no. 2, pp. 345–354, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Prydz, “Determinants of glycosaminoglycan (GAG) structure,” Biomolecules, vol. 5, no. 3, pp. 2003–2022, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Mende, C. Bednarek, M. Wawryszyn et al., “Chemical Synthesis of Glycosaminoglycans,” Chemical Reviews, vol. 116, no. 14, pp. 8193–8255, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Casu, A. Naggi, and G. Torri, “Re-visiting the structure of heparin,” Carbohydrate Research, vol. 403, pp. 60–68, 2015. View at Publisher · View at Google Scholar
  8. T. W. Barrowcliffe, “Heparin:, A Century of Progress. In:Heparin:A Century of Progress,” in Mulloy B. CPP, pp. 4–17, Springer Berlin, Berlin, Germany, 1st edition, 2012. View at Google Scholar
  9. J. Hirsh and V. Fuster, “Guide to anticoagulant therapy part 1: heparin,” English J, pp. 933–938, 2001. View at Google Scholar
  10. L. Galvan, “Effects of heparin on wound healing,” Journal of Wound Ostomy & Continence Nursing, vol. 23, no. 4, pp. 224–226, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. R. J. Ludwig, “Therapeutic use of heparin beyond anticoagulation,” Current Drug Discovery Technologies, vol. 6, no. 4, pp. 281–289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Balagurunathan, H. Nakato, H. Desai, and R. Umesh, Eds.“Methods in molecular biology,” in Glycosaminoglycans: Chemistry and Biology, pp. 3–619, Springer New York Heidelberg Dordrecht London, New York, USA, 2015.
  13. E. Gray, B. Mulloy, and T. W. Barrowcliffe, “Heparin and low-molecular-weight heparin,” Thrombosis and Haemostasis, vol. 99, no. 5, pp. 807–818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. N. S. Gandhi and R. L. Mancera, “The structure of glycosaminoglycans and their interactions with proteins,” Chemical Biology & Drug Design, vol. 72, no. 6, pp. 455–482, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. H. B. Nader, C. C. Lopes, H. A. O. Rocha, E. A. Santos, and C. P. Dietrich, “Heparins and heparinoids: Occurrence, structure and mechanism of antithrombotic and hemorrhagic activities,” Current Pharmaceutical Design, vol. 10, no. 9, pp. 951–966, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Hirsh, T. E. Warkentin, S. G. Shaughnessy et al., “Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety,” CHEST, vol. 119, no. 1, pp. 64S–94S, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Kemp and R. J. Linhardt, “Heparin-based nanoparticles,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 2, no. 1, pp. 77–87, 2010. View at Publisher · View at Google Scholar
  18. S. E. Sakiyama-Elbert, “Incorporation of heparin into biomaterials,” Acta Biomaterialia, vol. 10, no. 4, pp. 1581–1587, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Guo and H. Yan, “Preparation and characterization of heparin-stabilized gold nanoparticles,” Journal of Carbohydrate Chemistry, vol. 27, no. 5, pp. 309–319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Huang and X. Yang, “Synthesis of polysaccharide-stabilized gold and silver nanoparticles: a green method,” Carbohydrate Research, vol. 339, no. 15, pp. 2627–2631, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. D. P. Rodríguez-Torres, L. A. Díaz-Torres, P. Salas, C. Rodríguez-González, and M. Olmos-López, “UV photochemical synthesis of heparin-coated gold nanoparticles,” Gold Bulletin, vol. 47, no. 21, pp. 21–31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. H.-S. Kim, S. H. Jun, Y. K. Koo, S. Cho, and Y. Park, “Green synthesis and nanotopography of heparin-reduced gold nanoparticles with enhanced anticoagulant activity,” Journal of Nanoscience and Nanotechnology, vol. 13, no. 3, pp. 2068–2076, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Vismara, A. Valerio, A. Coletti et al., “Non-covalent synthesis of metal oxide nanoparticle-heparin hybrid systems: a new approach to bioactive nanoparticles,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 13463–13481, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Silvestri, A. Pezzella, G. Luciani, A. Costantini, F. Tescione, and F. Branda, “Heparin conjugated silica nanoparticle synthesis,” Materials Science and Engineering C: Materials for Biological Applications, vol. 32, no. 7, pp. 2037–2041, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. M.-A. Shahbazi and M. Hamidi, “The impact of preparation parameters on typical attributes of chitosan-heparin nanohydrogels: Particle size, loading efficiency, and drug release,” Drug Development and Industrial Pharmacy, vol. 39, no. 11, pp. 1774–1782, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M.-A. Shahbazi, M. Hamidi, and S. Mohammadi-Samani, “Preparation, optimization, and in-vitro/in-vivo/ex-vivo characterization of chitosan-heparin nanoparticles: Drug-induced gelation,” Journal of Pharmacy and Pharmacology, vol. 65, no. 8, pp. 1118–1133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. Y.-C. Kuo and K.-H. Shih, “Loading efficiency and surface conductance of heparin-modified poly(lactide-co-glycolide) nanoparticles,” Colloids and Surfaces B: Biointerfaces, vol. 71, no. 2, pp. 282–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Boddohi, N. Moore, P. A. Johnson, and M. J. Kipper, “Polysaccharide-based polyelectrolyte complex nanoparticles from chitosan, heparin, and hyaluronan,” Biomacromolecules, vol. 10, no. 6, pp. 1402–1409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Liu, Y. Jiao, F. Liu, and Z. Zhang, “Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation,” Journal of Biomedical Materials Research Part A, vol. 83, no. 3, pp. 806–812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. S. C. Wuang, K. G. Neoh, E.-T. Kang, D. W. Pack, and D. E. Leckband, “Heparinized magnetic nanoparticles: In-vitro assessment for biomedical applications,” Advanced Functional Materials, vol. 16, no. 13, pp. 1723–1730, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Nurunnabi, Z. Khatun, W. C. Moon, G. Lee, and Y. K. Lee, “Heparin based nanoparticles for cancer targeting and noninvasive imaging,” Quant Imaging Med Surg, vol. 2, no. 3, pp. 219–226, 2012. View at Google Scholar
  32. N. M. Acquisto, “Reference module in biomedical sciences,” in Encyclopedia of Toxicology Michael Caplan, pp. 837–839, Elsevier, 3rd edition, 2014. View at Google Scholar
  33. M. H. Forouzanfar et al., “GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990 2015: a systematic analysis for the global burden of disease,” Lancet, vol. 388, no. 10053, pp. 1659–1724, 2016. View at Google Scholar
  34. A. Sudhakar, “History of cancer, ancient and modern treatment methods,” Journal of Cancer Science and Therapy, vol. 1, no. 2, pp. 1–4, 2010. View at Google Scholar
  35. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. K. B. Sutradhar and M. L. Amin, “Nanotechnology in Cancer Drug Delivery and Selective Targeting,” ISRN Nanotechnology, vol. 2014, pp. 1–12, 2014. View at Publisher · View at Google Scholar
  37. V. Sanna, N. Pala, and M. Sechi, “Targeted therapy using nanotechnology: focus on cancer,” International Journal of Nanomedicine, vol. 9, no. 1, pp. 467–483, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Li, K. M. Huh, Y. Lee, and S. Y. Kim, “Design of a multifunctional heparin-based nanoparticle system for anticancer drug delivery,” Macromolecular Research, vol. 18, no. 2, pp. 153–161, 2010. View at Publisher · View at Google Scholar
  39. L. R. Zacharski and J. T. Loynes, “The heparins and cancer,” Current Opinion in Pulmonary Medicine, vol. 8, no. 1070–5287, pp. 379–382, 2002. View at Google Scholar
  40. R. Castelli, F. Porro, and P. Tarsia, “The heparins and cancer: review of clinical trials and biological properties,” Vascular Medicine, vol. 9, no. 3, pp. 205–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Noble, “Heparins and cancer survival: where do we stand?” Thrombosis Research, vol. 133, Supplement 2, pp. S133–S138, 2014. View at Publisher · View at Google Scholar
  42. T. M. H. Niers, C. P. W. Klerk, M. DiNisio et al., “Mechanisms of heparin induced anti-cancer activity in experimental cancer models,” Critical Review in Oncology/Hematology, vol. 61, no. 3, pp. 195–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. (NIH) NCI, A to Z List of Cancer Drugs [Internet], 2017, https://www.cancer.gov/about-cancer/treatment/drugs.
  44. K. Park, G. Y. Lee, Y.-S. Kim et al., “Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity,” Journal of Controlled Release, vol. 114, no. 3, pp. 300–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. N. U. Khaliq, F. C. Sandra, D. Y. Park et al., “Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy,” Biomaterials, vol. 101, pp. 131–142, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Zhang, H. Xiong, F. Z. Dahmani et al., “Combination chemotherapy of doxorubicin, all-trans retinoic acid and low molecular weight heparin based on self-assembled multi-functional polymeric nanoparticles,” Nanotechnology, vol. 26, no. 14, Article ID 145101, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Park, K. Kim, I. C. Kwon et al., “Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates,” Langmuir, vol. 20, no. 26, pp. 11726–11731, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Mei, Y. Liu, C. Xia, Y. Zhou, Z. Zhang, and Q. He, “Polymer-drug nanoparticles combine doxorubicin carrier and heparin bioactivity functionalities for primary and metastatic cancer treatment,” Molecular Pharmaceutics, vol. 14, no. 2, pp. 513–522, 2017. View at Publisher · View at Google Scholar · View at Scopus
  49. W. She, N. Li, K. Luo et al., “Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy,” Biomaterials, vol. 34, no. 9, pp. 2252–2264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Y. Cheang, Z. H. Xing, Z. L. Li et al., “Delivery of AIB1 siRNA by Ca2+/PEI/heparin composite nanoparticles effectively inhibits the growth of human breast cancer,” Journal of Materials Chemistry B, vol. 3, no. 38, pp. 7623–7630, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. W. Hu, L. Cheng, L. Cheng et al., “Redox and pH-responsive poly (amidoamine) dendrimer-poly (ethylene glycol) conjugates with disulfide linkages for efficient intracellular drug release,” Colloids and Surfaces B: Biointerfaces, vol. 123, pp. 254–263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. Q. Guo, X. Li, Y. Yang et al., “Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(l-lactide) grafted polyethylenimine cationic nanoparticles,” Journal of Biomedical Nanotechnology, vol. 10, no. 2, pp. 227–237, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. Y.-C. Yang, J. Cai, J. Yin, J. Zhang, K.-L. Wang, and Z.-T. Zhang, “Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers,” Carbohydrate Polymers, vol. 136, Article ID 10325, pp. 782–790, 2016. View at Publisher · View at Google Scholar · View at Scopus
  54. C.-K. Lai, Y.-L. Lu, J.-T. Hsieh et al., “Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy,” Nanomedicine, vol. 9, no. 6, pp. 803–817, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. I.-C. Sun, D.-K. Eun, J. H. Na et al., “Heparin-Coated gold nanopartieles for liver-Specific CT imaging,” Chemistry - A European Journal, vol. 15, no. 48, pp. 13276–13347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Liu, H. Xu, C. Zhang et al., “Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer,” Pharmaceutical Research, vol. 33, no. 11, pp. 2828–2843, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. Z. Khatun, M. Nurunnabi, K. J. Cho, Y. Byun, Y. H. Bae, and Y.-K. Lee, “Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates,” Journal of Controlled Release, vol. 177, no. 1, pp. 64–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Garg, V. Patel, R. Sharma, A. Jain, and A. K. Yadav, “Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil,” Artificial Cells, Nanomedicine and Biotechnology, vol. 4, pp. 1–10, 2016. View at Google Scholar
  59. M. Fazilati, “Anti-neoplastic Applications of Heparin Coated Magnetic Nanoparticles Against Human Ovarian Cancer,” Journal of Inorganic and Organometallic Polymers and Materials, vol. 24, no. 3, pp. 551–559, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Liu, M. Gou, T. Yi et al., “The enhanced antitumor effects of biodegradable cationic heparin-polyethyleneimine nanogels delivering HSulf-1 gene combined with cisplatin on ovarian cancer,” International Journal of Oncology, vol. 41, no. 4, pp. 1504–1512, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. F. Yang, M. Gou, H. Deng et al., “Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels,” Oncology Reports, vol. 28, no. 2, pp. 668–676, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Hou, J. Yao, J. Zhou, and Q. Zhang, “Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system,” Biomaterials, vol. 33, no. 21, pp. 5431–5440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Dai, J. Li, B. Zhang, J. Liu, Z. Luo, and K. Cai, “Redox-responsive nanocarrier based on heparin end-capped mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo,” Langmuir, vol. 30, no. 26, pp. 7867–7877, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Yang, Q. F. Guo, J. R. Peng et al., “Doxorubicin-conjugated heparin-coated superparamagnetic iron oxide nanoparticles for combined anticancer drug delivery and magnetic resonance imaging,” Journal of Biomedical Nanotechnology, vol. 12, no. 11, pp. 1963–1974, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. X.-H. Peng, Y. Wang, D. Huang et al., “Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin- cisplatin nanoparticles,” ACS Nano, vol. 5, no. 12, pp. 9480–9493, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Liang, D. Zhao, C.-Q. Wang, J.-Y. Zong, R.-X. Zhuo, and S.-X. Cheng, “Facile preparation of heparin/CaCO3/CaP hybrid nano-carriers with controllable size for anticancer drug delivery,” Colloids and Surfaces B: Biointerfaces, vol. 102, pp. 783–788, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. T. H. Tran, B.-C. Bae, Y.-K. Lee, K. Na, and K. M. Huh, “Heparin-folate-retinoic acid bioconjugates for targeted delivery of hydrophobic photosensitizers,” Carbohydrate Polymers, vol. 92, no. 2, pp. 1615–1624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. V. Revuri, J. Cho, and Y. Lee, “Photosensitizer conjugated iron oxide nanoparticles for simultaneous in vitro magneto-fluorescent imaging guided photodynamic therapy,” Chemical Communications, vol. 51, pp. 5687–5690, 2015. View at Google Scholar
  69. K. H. Bae, H. Mok, and T. G. Park, “Synthesis, characterization, and intracellular delivery of reducible heparin nanogels for apoptotic cell death,” Biomaterials, vol. 29, no. 23, pp. 3376–3383, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Li, B.-C. Bae, T. H. Tran, K. H. Yoon, K. Na, and K. M. Huh, “Self-quenchable biofunctional nanoparticles of heparin-folate- photosensitizer conjugates for photodynamic therapy,” Carbohydrate Polymers, vol. 86, no. 2, pp. 708–715, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Nafiujjaman, V. Revuri, M. Nurunnabi, K. Jae Cho, and Y. Lee, “Photosensitizer conjugated iron oxide nanoparticles for simultaneous in vitro magneto-fluorescent imaging guided photodynamic therapy,” Chemical Communications, vol. 51, pp. 5687–5690, 2015. View at Google Scholar
  72. G. Baier, S. Winzen, C. Messerschmidt et al., “Heparin-based nanocapsules as potential drug delivery systems,” Macromolecular Bioscience, vol. 15, no. 6, pp. 765–776, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Argyo, V. Cauda, H. Engelke, J. Rädler, G. Bein, and T. Bein, “Heparin-coated colloidal mesoporous silica nanoparticles efficiently bind to antithrombin as an anticoagulant drug-delivery system,” Chemistry - A European Journal, vol. 18, no. 2, pp. 428–432, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. B. E. Dunn, H. Cohen, and M. J. Blaser, “Helicobacter pylori,” Clinical Microbiology Reviews, vol. 10, no. 4, pp. 720–724, 1997. View at Google Scholar
  75. J. G. Kusters, A. H. M. van Vliet, and E. J. Kuipers, “Pathogenesis of Helicobacter pylori infection,” Clinical Microbiology Reviews, vol. 19, no. 3, pp. 449–490, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Suerbaum and P. Michetti, “Helicobacter pylori infection,” The New England Journal of Medicine, vol. 347, no. 15, pp. 1175–1186, 2002. View at Google Scholar
  77. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence consensus report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. B. Stenström, A. Mendis, and B. Marshall, “Helicobacter pylori: The latest in diagnosis and treatment,” Australian Family Physician, vol. 37, no. 8, pp. 608–612, 2008. View at Google Scholar · View at Scopus
  79. C.-H. Chang, W.-Y. Huang, C.-H. Lai et al., “Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori,” Acta Biomaterialia, vol. 7, no. 2, pp. 593–603, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. Y.-H. Lin, J.-H. Lin, S.-C. Chou et al., “Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: In vitro and in vivo study,” Nanomedicine, vol. 10, no. 1, pp. 57–71, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. Y.-H. Lin, S.-C. Tsai, C.-H. Lai, C.-H. Lee, Z. S. He, and G.-C. Tseng, “Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori,” Biomaterials, vol. 34, no. 18, pp. 4466–4479, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Vance-Bryan, D. R. P. Guay, and J. C. Rotschafer, “Clinical Pharmacokinetics of Ciprofloxacin,” Clinical Pharmacokinetics, vol. 19, no. 6, pp. 434–461, 1990. View at Publisher · View at Google Scholar · View at Scopus
  83. G. V. Kumar, C.-H. Su, and P. Velusamy, “Ciprofloxacin loaded genipin cross-linked chitosan/heparin nanoparticles for drug delivery application,” Materials Letters, vol. 180, no. 2016, pp. 119–122, 2016. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Chen, S. Li, K. Liu, G. Ma, and X. Yan, “Co-Assembly of Heparin and Polypeptide Hybrid Nanoparticles for Biomimetic Delivery and Anti-Thrombus Therapy,” Small, vol. 34, pp. 4719–4725, 2016. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Bellido, T. Hidalgo, M. V. Lozano et al., “Heparin-Engineered Mesoporous Iron Metal-Organic Framework Nanoparticles: Toward Stealth Drug Nanocarriers,” Advanced Healthcare Materials, vol. 4, no. 8, pp. 1246–1257, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Salmaso and P. Caliceti, “Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers,” Journal of Drug Delivery, vol. 2013, pp. 1–19, 2013. View at Publisher · View at Google Scholar
  87. M. Socha, P. Bartecki, C. Passirani et al., “Stealth nanoparticles coated with heparin as peptide or protein carriers,” Journal of Drug Targeting, vol. 17, no. 8, pp. 575–585, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Suetens, “Fundamentals of medical imaging,” in Fundamentals of Medical Imaging, pp. 128–158, 2009. View at Google Scholar
  89. S. K. Nune, P. Gunda, P. K. Thallapally, Y.-Y. Lin, M. Laird Forrest, and C. J. Berkland, “Nanoparticles for biomedical imaging,” Expert Opinion on Drug Delivery, vol. 6, no. 11, pp. 1175–1194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. C. M. Maguire, O. K. Mahfoud, T. Rakovich et al., “Heparin conjugated quantum dots for in vitro imaging applications,” Nanomedicine: Nanotechnology, Biology and Medicine, vol. 10, no. 8, pp. 1853–1861, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. Z. Khatun, M. Nurunnabi, D. Y. Lee et al., “Optical imaging, biodistribution and toxicity of orally administered quantum dots loaded heparin-deoxycholic acid,” Macromolecular Research, vol. 23, no. 7, pp. 686–695, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. Z. Khatun, M. Nurunnabi, K. J. Cho, and Y. Lee, “Imaging of the GI tract by QDs loaded heparin-deoxycholic acid (DOCA) nanoparticles,” Carbohydrate Polymers, vol. 90, no. 4, pp. 1461–1468, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Wang, D. Ma, Q. Lu et al., “An unusual role of folate in the self-assembly of heparin-folate conjugates into nanoparticles,” Nanoscale, vol. 7, no. 37, pp. 15185–15190, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. H. Hwang and D. Y. Lee, “Magnetic resonance imaging using heparin-coated superparamagnetic iron oxide nanoparticles for cell tracking in vivo,” Quantitative Imaging in Medicine and Surgery, vol. 2, no. 2, pp. 118–123, 2012. View at Google Scholar
  95. N. P. Gonçalves, H. Oliveira, A. P. Pêgo, and M. J. Saraiva, “A novel nanoparticle delivery system for in vivo targeting of the sciatic nerve: Impact on regeneration,” Nanomedicine, vol. 7, no. 8, pp. 1167–1180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. O. Jeon, S. J. Song, S. Kang, A. J. Putnam, and B. Kim, “Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(l-lactic-co-glycolic acid) scaffold,” Biomaterials, vol. 28, no. 17, pp. 2763–2771, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. S. E. Kim, O. Jeon, J. B. Lee et al., “Enhancement of ectopic bone formation by bone morphogenetic protein-2 delivery using heparin-conjugated PLGA nanoparticles with transplantation of bone marrow-derived mesenchymal stem cells,” Journal of Biomedical Science, vol. 15, no. 6, pp. 771–777, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. Yang, H. Tang, A. Köwitsch et al., “Novel mineralized heparin-gelatin nanoparticles for potential application in tissue engineering of bone,” Journal of Materials Science: Materials in Medicine, vol. 25, no. 3, pp. 669–680, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Wang, L. Tan, D. Deng et al., “Novel stable cytokine delivery system in physiological pH solution: Chitosan oligosaccharide/ heparin nanoparticles,” International Journal of Nanomedicine, vol. 10, pp. 3417–3427, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Vijaya Sudhakar, D. Srinivasa Rao, and P. Naga Babu, “K.R.S.Samba Siva Rao SP. Polysaccharide based synthesis characterization of heparin stabilized silver nanoparticles and its antibacterial activity,” Drug Invention Today, vol. 6, no. 1, pp. 77–83, 2014. View at Google Scholar
  101. M. M. Kemp, A. Kumar, D. Clement, P. Ajayan, S. Mousa, and R. J. Linhardt, “Hyaluronan- and heparin-reduced silver nanoparticles with antimicrobial properties,” Nanomedicine, vol. 4, no. 4, pp. 421–429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. C. Sun, Y. Niu, F. Tong et al., “Preparation of novel electrochemical glucose biosensors for whole blood based on antibiofouling polyurethane-heparin nanoparticles,” Electrochimica Acta, vol. 97, pp. 349–356, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Park, A.-R. Im, Y. N. Hong, C.-K. Kim, and Y. S. Kim, “Detection of malathion, fenthion and methidathion by using heparin-reduced gold nanoparticles,” Journal of Nanoscience and Nanotechnology, vol. 11, no. 9, pp. 7570–7578, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. M. D. P. Rodríguez-Torres, L. A. Díaz-Torres, and S. Romero-Servin, “Heparin assisted photochemical synthesis of gold nanoparticles and their performance as SERS substrates,” International Journal of Molecular Sciences, vol. 15, no. 10, pp. 19239–19252, 2014. View at Publisher · View at Google Scholar · View at Scopus